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ABSTRACT The emergence of multidrug-resistant bacteria 
creates an urgent need for alternative antibiotics with new 
mechanisms of action. In this study, we synthesized a 
novel type of antimicrobial agent, Ac r3-NLS, by conjugating 
hydrophobic acridines to the N-terminus of a nuclear 
localization sequence (NLS), a short cationic peptide. To 
further improve the antimicrobial activity of our agent, 
dimeric (Acr3-NLS)2 was simultaneously synthesized by 
joining two monomeric Acr3-NLS together via a disulfide 
linker. Our results show that Acr3-NLS and especially (Acr3-
NLS)2 display signiﬁ cant antimicrobial activity against gram-
negative and gram-positive bacteria compared to that of the 
NLS. Subsequently, the results derived from the study on the 
mechanism of action demonstrate that Acr3-NLS and (Acr3-
NLS)2 can kill bacteria by membrane disruption and DNA 
binding. The double targets—cell membrane and intracellular 
DNA—will reduce the risk of bacteria developing resistance to 
Acr3-NLS and (Acr3-NLS)2. Overall, this study provides a novel 
strategy to design highly eﬀ ective antimicrobial agents with a 
dual mode of action for infection treatment.
KEYWORDS acridine, nuclear localization sequence, con-
jugate, antimicrobial activity, mechanism of action
1 Introduction
Infectious diseases caused by bacteria affect millions of 
people throughout the world. The discovery of antibiotics 
had a profound impact on human health. Unfortunately, with 
the frequent emergence of drug-resistant bacterial strains, 
traditional antibiotics are becoming increasingly ineffective 
[1]. This trend prompts an urgent need for a new class of anti-
biotics with novel mechanisms of action.
Th e nuclear localization sequence (NLS, PKKKRKV) of 
SV40 T large antigen, an extensively studied peptide, can fa-
cilitate the nuclear transport of heterologous molecules [2–4]. 
Interestingly, the NLS was reported to show antimicrobial 
activity against both gram-negative and gram-positive bacte-
ria, although its mechanism of action remains obscure and its 
antimicrobial activity is relatively low [5]. 
Acridine (Acr), a heteroaromatic polycyclic molecule, is 
well known for its DNA intercalating abilities and pharma-
cological properties [6]. A considerable number of acridine 
derivatives have been synthesized and used as antimicrobial, 
antimalarial, and anticancer drugs [7–10]. The first clinical 
use of acridines as antimicrobial agents occurred in 1917 [10]. 
The emergence of penicillins with greater therapeutic ef-
ﬁ cacy eclipsed acridines in antimicrobial therapy. However, 
the serious problem of antibiotic resistance has once again 
directed considerable attention toward acridines [10].
Attaching small molecule drugs to peptides has been 
proved to be an effective strategy offering a variety of 
benefits, such as increasing aqueous solubility, improving 
pharmacokinetics, and overcoming drug resistance [11, 12]. 
In this study, we attempt to design a novel type of effective 
antimicrobial agent by conjugating acridines to an NLS. Thus 
Acr3-NLS was designed and synthesized by attaching three 
Lys(acridine) to the N-terminus of the NLS in this study. 
Dimerization has been reported to be a useful strategy to 
enhance the antimicrobial potency and resistance to prote-
ases of antimicrobial peptides [13, 14]. Therefore, to improve 
the antimicrobial activity of our agent, we also synthesized 
the dimeric (Acr3-NLS)2 by joining two Acr3-NLS monomers 
together at the C-terminus via a disulﬁ de linker, which has 
been extensively used for drug conjugation [15]. Figure 1 
presents these conjugates. We subsequently evaluated the 
antimicrobial activity and studied the action mechanisms of 
Acr3-NLS and (Acr3-NLS)2.
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2 Materials and methods
2.1 Peptide synthesis and puriﬁ cation
The NLS and Acr3-NLS were synthesized on a p-methyl-
benzhydrylamine (MBHA) resin using the standard Fmoc-
chemistry-based strategy. Following a procedure reported in 
previous literature [16], Fmoc-Lys(acridine) was synthesized 
and coupled as an amino acid. The synthesis of (Acr3-NLS)2 
was performed according to our previously reported pro-
cedure [17]. All crude peptides were purified by reversed-
phase high-performance liquid chromatography (RP-HPLC) 
on a C18 column and then characterized by electrospray 
ionization mass spectrometry (ESI-MS). Purity analysis was 
checked by analytical RP-HPLC, and peptides were eluted 
using a liner gradient of 5%–95% acetonitrile in 0.1% triﬂ uo-
roacetic acid at a ﬂ ow rate of 1 mL· min–1 within 30 min. The 
retention time (tR) of each peptide was determined when the 
peak was at its maximum height. 
2.2 Antimicrobial activity assay
Gram-negative (Escherichia coli, ATCC 25922; Pseudomonas 
aeruginosa, ATCC 27853) and gram-positive (Bacillus subtilis, 
ATCC 23857; Staphylococcus aureus, ATCC 25923) bacteria were 
cultured in Mueller-Hinton (MH) broth at 37 °C. The anti-
microbial activities of the agents against gram-negative and 
gram-positive bacteria were measured using a standard seri-
al dilution method. Brieﬂ y, 100 μL of 2-fold serial diluted ali-
quots of the agents in a range from 1 μmol· L–1 to 128 μmol· L–1 
in MH broth were added to 96-well plates containing 100 μL 
of diluted bacterial cells (106 CFU· mL–1, C FU is short for colo-
ny forming unit). After incubation for 18–20 h, the minimum 
inhibitory concentration (MIC) was detected. Controls were 
performed in the absence of agents. The experiment was con-
ducted in triplicate.
2.3 Time-killing assay
The killing kinetic of the conjugates against E. coli was ana-
lyzed by a time-killing assay. E. coli was grown to log phase 
and diluted to 106 CFU· mL–1 in MH broth. The conjugates 
were added to the bacterial suspensions at concentrations of 
0.5-fold, 1-fold, and 2-fold of the MIC. At 0, 15 min, 30 min, 
60 min, 90 min, and 120 min, 100 μL of cell suspension was 
collected and diluted into growth medium, then plated onto 
MH agar plates. Colonies were counted after peptide treat-
ment for 24 h. The experiment was conducted in triplicate.
2.4 Propidium iodide uptake assay
To verify the membrane-lytic activity of the conjugates, we 
used a propidium iodide (PI) uptake assay. E. coli was grown 
to log phase and diluted to 106 CFU· mL–1 in MH broth. The 
medium, with 1 mL of phosphate-buffered saline (PBS) con-
taining E. coli with a density of 1 × 106 CFU· mL–1, was added 
to the dish, and E. coli cells were treated with 1-fold MIC of 
the conjugates at 37 °C. After incubation at different time in-
tervals, PI was added and further incubated for 10 min, and 
PI uptake was observed using a laser confocal scanning mi-
croscope.
2.5 Scanning electron microscopy
For scanning electron microscopy (SEM) sample prepara-
tion, E. coli cells were washed and re-suspended at 5 × 108 
CFU· mL–1 in PBS and incubated with the conjugates (1-fold 
MIC) at 37 °C for 1 h. Subsequently, the cells were centrifuged 
for 5 min at 10 000 r· min–1 and ﬁ xed with 3% glutaraldehyde 
at 4 °C. All ﬁ xed cells were impregnated in 2.5% tannic acid 
(Sigma) for 2 d, and counter-fixed with 2% osmium tetrox-
ide (Sigma) for 2 h, followed by dehydration in ethanol and 
drying in a critical point dryer (Ion Tech, Teddington). After 
coating with gold, E. coli cells were observed using a scan-
ning electron microscope (JSM-6380Lv).
2.6 Hemolysis assay
Freshly collected mice blood was centrifuged to remove the 
buffy coat, and the obtained erythrocytes were washed three 
times with PBS, centrifuged for 10 min at 1000g (g = 9.8 m· s–2), 
and re-suspended in PBS to 4% (V/V). 100 μL of the conju-
gates solution at various concentrations was added to a 96-
well plate containing 100 μL of erythrocyte suspension. Cells 
treated with PBS and 0.1% Triton X-100 were as 0 and 100% 
hemolysis, respectively. After treatment for 1 h, the plates 
were centrifuged at 1000g for 10 min, and 100 μL of superna-
tants was transferred to a 96-well plate. The release of hemo-
globin was determined using a microplate reader at 450 nm.
2.7 DNA binding assay
Gel retardation experiments were performed to evaluate the 
DNA binding ability of the conjugates. E. coli ATCC 25922 
genomic DNA was extracted using a TIANamp Bacteria 
DNA Kit. 10 μL of genomic DNA (approximately 400 ng) was 
dissolved in TE buffer and mixed with an e qual volume of 
varying concentrations of the conjugates. The reaction mix-
tures were incubated at room temperature for 30 min. The 
mixtures and native loading buffer were then subjected to gel 
electrophoresis on a 1% agarose gel. The migration of DNA 
was detected by the ﬂ uorescence of ethidium bromide. 
2.8 Cell uptake of conjugates
E. coli cells were incubated with the conjugates at 0.5-fold 
MIC for 1 h. The cells were then washed three times with 
PBS. Images were taken with an inverted Zeiss LSM 710 con-
Figure 1. The structures of Acr3-NLS and (Acr3-NLS)2. 
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focal microscope. Excitation was performed by a 405 nm line, and a ﬂ uorescence 
emission maximum at 487 nm was observed. Differential interference contrast (DIC) 
images were taken along with both fluorescence channels, and no bleedthrough 
was observed during co-localization studies with these parameters.
3 Results and discussion
3.1 Antimicrobial activity of conjugates
The emergence of multidrug-resistant bacteria creates an urgent need for alterna-
tive antibiotics with new mechanisms of action. In this study, we synthesized a 
novel type of antimicrobial agent by conjugating acridines to the N-terminus of an 
NLS. The antimicrobial activity of all agents was determined against two gram-
negative bacteria (E. coli and P. aeruginosa), and two gram-positive bacteria (S. au-
reus and B. subtilis). Table 1 summarizes the MIC of all agents. Although the NLS 
was reported to exhibit antimicrobial activity [5], our results showed that it did 
not kill bacteria at the concentrations tested in this study. As expected, Acr3-NLS 
and dimeric (Acr3-NLS)2 displayed signiﬁ cant antimicrobial activity against gram-
negative and gram-positive bacteria compared to that of the NLS. Importantly, the 
antimicrobial activity of dimeric (Acr3-NLS)2 was signiﬁ cantly higher than that of 
Acr3-NLS. We subsequently investigated the time-killing activity of Acr3-NLS and 
(Acr3-NLS)2 against E. coli. As shown in Figure 2, our results showed that both Acr3-
NLS and (Acr3-NLS)2 can kill bacteria within a short time, especially at higher con-
centrations. In addition, the killing activity of dimeric (Acr3-NLS)2 was signiﬁ cantly 
faster than that of Acr3-NLS at the same MIC. Based on their rapid bacteria-killing 
activity and physicochemical properties, we speculate that Acr3-NLS and (Acr3-
NLS)2 can kill bacteria by disrupting their membranes, like most antimicrobial 
peptides [18, 19]. 
physical processes [18]. 
Firstly, we adopted the PI uptake as-
say, a typical method of studying mem-
brane disruption by antimicrobial pep-
tides, in order to study the change in 
the integrity of the cell membranes af-
ter Acr3-NLS or (Acr3-NLS)2 treatment. 
PI is a ﬂ uorescent molecule that can be 
excluded by the membranes of viable 
cells but that can pass through dam-
aged plasma membranes. As shown 
in Figure 3, our results showed that PI 
could rapidly enter E. coli cells after 
Acr3-NLS or (Acr3-NLS)2 treatment, in-
dicating that the E. coli cell membranes 
were damaged. We observed the subtle 
morphological changes of E. coli mem-
branes after Acr3-NLS or (Acr3-NLS)2 
treatment using SEM. As shown in 
Figure 4, E. coli treated with conjugates 
appeared to display the formation of 
blebs on the cell surface, which is likely 
to represent pore formation, while un-
treated E. coli showed a normal smooth 
surface. The result derived from SEM 
was in agreement with that derived 
from the PI uptake assay, confirming 
that Acr3-NLS and (Acr3-NLS)2 can kill 
bacteria via membrane disruption, just 
like many naturally occurring antimi-
crobial peptides. Membrane-lytic activ-
ity may endow Acr3-NLS and (Acr3-
NLS)2 with the following advantages: 
① Unlike traditional antibiotics, they 
can be used to kill drug-resistant bac-
teria with a new mechanism of mem-
brane damage; ② it will be very dif-
ﬁ cult for bacteria to develop resistance 
to them, because reconstruction of the 
membrane system is impossible.
Cationicity and hydrophobicity play 
an important role in the membrane-
lytic activity of antimicrobial peptides 
[20–22]. Positive charges give antimicro-
bial peptides an electrostatic afﬁ nity to 
the outer leaﬂ et of bacterial membranes, 
whereas hydrophobicity can force the 
insertion of antimicrobial peptides into 
the hydrophobic bacterial membranes 
[23]. An appropriate increase in positive 
charge and hydrophobicity will contrib-
ute to improving the membrane-lytic 
activity and bacteria-killing activity of 
antimicrobial peptides [19, 21, 24]. The 
NLS in this study is a cationic peptide 
containing ﬁ ve basic amino acids (four 
lysines and one arginine), but only one 
hydrophobic amino acid. Consequently, 
it is very hard for the NLS to enter a 
Table 1. Amino acid sequence, physicochemical properties, and antimicrobial activity of NLS and its 
analogues containing acridine.
Peptide Mcalc*(g.mol–1)
Mobs**
(g.mol–1)
tR$
(min)
MIC (µmol· L–1) 
E. coli P. aeruginosa S. aureus B. subtilis
NLS 984.6 985.6 11.4 > 128 > 128 > 128 > 128
Acr3-NLS 1901.7 1901.1 14.3 16 64 16 16
(Acr3-NLS)2 3801.4 3801.2 15.0 8 16 8 8
9-chloroacridine — — — > 128 > 128 > 128 > 128
Notes: * Calculated monoisotopic molar masses. ** Observed monoisotopic masses. $ Hydrophobicity 
represented as tR was measured by RP-HPLC.
Figure 2. Time-killing activity of (a) Acr3-NLS and (b) (Acr3-NLS)2 at different concentrations against E. 
coli. Representative of triplicate experiments.
3.2 Membrane-lytic activity of conjugates
Antimicrobial peptides are cationic short peptides with an overall content of 50% 
hydrophobic residues, which exhibit potent broad-spectrum antimicrobial proper-
ties [19]. Unlike traditional antibiotics that have speciﬁ c molecular targets, antimi-
crobial peptides bind selectively and rapidly disrupt negatively charged bacterial 
membranes, rather than neutral mammalian cell membranes, through a series of 
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bacterial membrane and form stable pores because of its low 
hydrophobicity [25]. In our previous study, we found that 
the attachment of hydrophobic camptothecin can turn the 
hydrophilic cell-penetrating peptide Tat into a membrane-
lytic peptide [26]. In this study, acridine might act as an ideal 
hydrophobic anchor to promote the membrane insertion and 
subsequent membrane disruption of the conjugates, resulting 
in increased antimicrobial activity. To evaluate the effect of 
acridine on the hydrophobicity of peptides, we determined 
the retention time (tR) of peptides using RP-HPLC, which is a 
particularly good method to represent apparent peptide hy-
drophobicity [24]. As shown in Table 1, the retention time of 
Acr3-NLS was signiﬁ cantly prolonged compared to that of the 
NLS, indicating that Acr3-NLS is more hydrophobic than the 
NLS. Therefore, the increased hydrophobicity of Acr3-NLS by 
conjugation with the hydrophobic end tag Lys(acridine) could 
account for its enhanced membrane-lytic activity. Likewise, 
dimeric (Acr3-NLS)2, which has increased hydrophobicity, 
displayed higher antimicrobial activity than monomeric 
Acr3-NLS.
3.3 Hemolytic activity of conjugates
Low toxicity against host cells is very important for the clini-
cal development of potent antimicrobial peptides. Hemolysis 
assay is the most commonly used procedure to assess the tox-
icity of antimicrobial peptides [27]. A high level of hydropho-
bicity generally enhances the interaction of antimicrobial pep-
tides with the neutral membranes of red blood cells, resulting 
in an increase in hemolytic activity [24]. Despite having more 
hydrophobicity than the NLS, Acr3-NLS did not display vir-
tual hemolysis even up to 200 μmol·L–1, which is far higher 
than its MIC (Figure 5). Although dimerization has been re-
ported to increase the hemolysis of antimicrobial peptides [28], 
the dimeric (Acr3-NLS)2 did not show signiﬁ cantly increased 
hemolysis compared to monomeric Acr3-NLS. Overall, our re-
sults demonstrated that Acr3-NLS and (Acr3-NLS)2 displayed 
low toxicity to normal cells, which means that higher drug 
concentrations can be used in infection therapy.
3.4 DNA binding activity of conjugates
Recently, more and more studies have revealed that mem-
brane disruption is not the only mec h an ism of action of anti-
Figure 3. The PI uptake in E.coli after Acr3-NLS and (Acr3-NLS)2 treatment 
at the concentration of 1 × MIC for different times.
Figure 4. Scanning electron micrographs of E.coli. (a) Control; (b) Acr3-NLS 
treatment; (c) (Acr3-NLS)2 treatment. The bacteria were treated with peptide at 
the concentration of 1 × MIC for 1 h. The control was done without peptides. 
Scale bar = 1 µm.
Figure 5. The hemolytic activities of NLS, Acr3-NLS, and (Acr3-NLS)2. 
Cells were treated with melittin at 10 µmol·L–1. Representative of triplicate 
experiments.
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microbial peptides. Some antimicrobial 
peptides have been reported to kill 
bacteria by interaction with one or more 
intracellular targets, such as nucleic 
acids and enzymes [29, 30]. Compared 
to other intracellular targets, cationic 
antimicrobial peptides preferentially at-
tack the anionic nucleic acids, resulting 
in bacterial death [30]. In our previous 
study, NK-18, a truncated peptide de-
rived from NK-lysin, was found to be 
able to kill bacteria not only by disrupt-
ing the bacterial membrane but also by 
binding to DNA [31]. Because nucleic 
acids are the established sites of action 
of acridine-derived antimicrobial agents 
in bacteria [10], we speculated that Acr3-
NLS and (Acr3-NLS)2, because they con-
ta in acridines, could also kill bacteria by 
binding to DNA and interfering with 
the synthesis of DNA. 
Firstly, gel retardation assay was 
used to evaluate the nucleic acid bind-
ing ability of the peptides. As shown in 
Figure 6, Acr3-NLS and especially (Acr3-
NLS)2 caused signiﬁ cant retardation of 
bacterial DNA mobility compared to 
the NLS, indicating that the presence 
of acridine remarkably enhanced the 
DNA binding ability of Acr3-NLS and 
(Acr3-NLS)2. However, in order to in-
teract with DNA, Acr3-NLS and (Acr3-
NLS)2 must first translocate across the 
bacterial membranes. Interestingly, 
more and more studies demonstrate 
that many antimicrobial peptides can 
translocate across cell membranes, 
much like cell-penetrating peptides, 
because of their similarities in charge, 
structure, and initial membrane in-
teractions [32]. Although the NLS was 
reported to overcome the nuclear mem-
brane barrier and to promote nuclear 
translocation, there are few reports on 
its translocation across the cell mem-
brane. In this study, we observed the 
cell uptake of Acr3-NLS and (Acr3-NLS)2 
in E. coli using confocal microscopy. As 
shown in Figure 7, both Acr3-NLS and 
(Acr3-NLS)2 could penetrate and accu-
mulate inside the E. coli cells, like many 
cell-penetrating peptides. According 
to the above results, we can infer that 
Acr3-NLS and (Acr3-NLS)2 can kill bac-
teria by disrupting the cell membrane 
and by interfering with the synthesis 
of DNA. The double targets—the cell 
Figure 6. The DNA-interacting effect of NLS, Acr3-NLS, and (Acr3-NLS)2. DNA binding ability assayed by 
determining the retardation of DNA migration.
Figure 7. The cell uptake of Acr3-NLS and (Acr3-NLS)2 in E. coli after treatment at the concentration of 
0.5 × MIC for 1 h.
membrane and intracellular DNA—minimize the chances of bacterial resistance to 
Acr3-NLS and (Acr3-NLS)2, as resistance would require the complete alteration of 
the cell membrane or the bypassing of several biochemical pathways.
4 Conclusions
In this study, we developed a new type of antimicrobial peptide by attaching acri-
dines to an NLS. Our new agents can kill bacteria through a double action mecha-
nism: Acridine can act as a membrane anchor to endow Acr3-NLS and (Acr3-NLS)2 
with membrane-lytic activity, and acridine can also enhance the DNA binding abil-
ity and subsequent bacteria-killing activity of Acr3-NLS and (Acr3-NLS)2. Therefore, 
Acr3-NLS and (Acr3-NLS)2 can effectively kill bacteria in a manner that is not easily 
affected by known bacterial resistance capabilities. Although much further work is 
needed to obtain a systematic evaluation of the future application of these agents, 
this study opens a new avenue to design a new type of antimicrobial peptide with 
multiple mechanisms of action.
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